Sandusky, OH – August 14, 2020 – — PAO Group, Inc. (OTC PINK: PAOG) after earlier today announcing the publication of an initial Goldman Small Cap Research Analyst Report, management now confirms a prompt second report coming from Goldman following PAOG’s soon to be filed up-to-date financial reports.
PAOG recently executed two acquisitions as part of an overall business revitalization strategy bringing the company into the cannabis biopharmaceutical sector. The revitalization strategy includes updating the company’s financial statements to make the company compliant with the OTC Markets’ “Current Information” reporting standard. Management anticipates the company could be “Current” as early as next week – no later than by the end of the month.
Goldman Small Cap Research is anticipated to file an updated analyst report once PAOG has achieved the “Current Information” standard.
See the Goldman Small Cap Research Analyst Report published today:
Under The Radar CBD Pharma Player Could Offer Major Upside
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.